AR070949A1 - COMPOUNDS DERIVED FROM SULFAMATE FOR MEDICAL USE, MEDICINES AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, PROCEDURES TO PREPARE THESE COMPOUNDS AND THEIR USE - Google Patents
COMPOUNDS DERIVED FROM SULFAMATE FOR MEDICAL USE, MEDICINES AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, PROCEDURES TO PREPARE THESE COMPOUNDS AND THEIR USEInfo
- Publication number
- AR070949A1 AR070949A1 ARP080104465A ARP080104465A AR070949A1 AR 070949 A1 AR070949 A1 AR 070949A1 AR P080104465 A ARP080104465 A AR P080104465A AR P080104465 A ARP080104465 A AR P080104465A AR 070949 A1 AR070949 A1 AR 070949A1
- Authority
- AR
- Argentina
- Prior art keywords
- bicyclo
- hept
- aryl
- formula
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula (1), en la que R1 y R2 se seleccionan independientemente del grupo que consiste en: hidrogeno, alquilo, cicloalquilo y arilo, de los que alquilo y cicloalquilo están opcionalmente sustituidos con al menos un sustituyente Y, y de los que arilo está opcionalmente sustituido con al menos un sustituyente Z, o en donde R1 y R2 forman, juntos; un anillo de 5 o 6 miembros que puede contener, adicionalmente, 1 a 2 heteroátomos seleccionados independientemente del grupo consistente en: nitrogeno, oxígeno y azufre, y dicho anillo de 5 o 6 miembros está sustituido opcionalmente con al menos un sustituyente Y; R3 se selecciona del grupo consistente en: (1S,2S,5S)-6,6-dimetil-biciclo[3.1.1]hept-2-ilo; (1R,2R,5R)-6,6-dimetil-biciclo[3.1.1]hept-2-ilo; (1R,2S,5R)-6,6-dimetil-biciclo[3.1.1]hept-2-ilo; (1R,4S)-biciclo[2.2.1]hept-2-ilo; (1S,4R)-3-metil-biciclo[2.2.1]hept-2-ilo; biciclo[2.2.2]oct-5-en-2-ilo; (4S)-biciclo[2.2.1]hept-5-en-2-ilo; (1S,2R,4S)-1,7,7-trimetil-biciclo[2.2.1]hept-2-ilo; (1R,2S,4R)-1,7,7-trimetil-biciclo[2.2.1]hept-2-ilo; (1R,2R,4R)-1,7,7-trimetil-biciclo[2.2.1]hept-2-ilo y ciclohexilo; n es de 0 a 3; Y se selecciona del grupo consistente en: alquilo, alcoxi, tioalquilo, arilo, CO-arilo, heteroarilo, amino y carboxialquilo; Z se selecciona del grupo consistente en: alquilo, alcoxi, tioalquilo, halogeno, arilo, CO-arilo, CN, heteroarilo y carboxialquilo; y sus sales, hidratos y solvatos fisiologicamente aceptables. Reivindicacion 6: Un medicamento que comprende un compuesto segun una cualquiera de las reivindicaciones 1 a 5, o una sal, hidrato o solvato farmacéuticamente aceptable del mismo. Reivindicacion 7: Una composicion farmacéutica que comprende: A) una cantidad farmacologicamente eficaz de un compuesto de la formula (1), segun cualquiera de las reivindicaciones 1 a 5, o una sal, hidrato o solvato farmacéuticamente aceptable del mismo, como ingrediente activo; y B) opcionalmente, al menos un vehículo farmacéuticamente aceptable y/o al menos una sustancia auxiliar farmacéuticamente aceptable. Reivindicacion 10: Un procedimiento para preparar un compuesto de la formula (1) segun cualquiera de las reivindicaciones 1 a 5, caracterizado porque compuestos de la formula (2) en los que Hal significa un halogeno, seleccionado del grupo consistente en cloro, y bromo, preferiblemente cloro, se hacen reaccionar con un alcohol de la formula (3) para dar compuestos de la formula (1). Reivindicacion 13: El uso de un compuesto segun cualquiera de las reivindicaciones 1 a 5 o de sus sales, hidratos y solvatos fisiologicamente aceptables, como medicamento para mamíferos, preferiblemente humanos.Claim 1: A compound of formula (1), wherein R1 and R2 are independently selected from the group consisting of: hydrogen, alkyl, cycloalkyl and aryl, of which alkyl and cycloalkyl are optionally substituted with at least one substituent Y, and of which aryl is optionally substituted with at least one substituent Z, or where R1 and R2 form, together; a 5 or 6 member ring which may additionally contain 1 to 2 heteroatoms independently selected from the group consisting of: nitrogen, oxygen and sulfur, and said 5 or 6 member ring is optionally substituted with at least one Y substituent; R3 is selected from the group consisting of: (1S, 2S, 5S) -6,6-dimethyl-bicyclo [3.1.1] hept-2-yl; (1R, 2R, 5R) -6,6-dimethyl-bicyclo [3.1.1] hept-2-yl; (1R, 2S, 5R) -6,6-dimethyl-bicyclo [3.1.1] hept-2-yl; (1R, 4S) -bicyclo [2.2.1] hept-2-yl; (1S, 4R) -3-methyl-bicyclo [2.2.1] hept-2-yl; bicyclo [2.2.2] oct-5-en-2-yl; (4S) -bicyclo [2.2.1] hept-5-en-2-yl; (1S, 2R, 4S) -1,7,7-trimethyl-bicyclo [2.2.1] hept-2-yl; (1R, 2S, 4R) -1,7,7-trimethyl-bicyclo [2.2.1] hept-2-yl; (1R, 2R, 4R) -1,7,7-trimethyl-bicyclo [2.2.1] hept-2-yl and cyclohexyl; n is 0 to 3; And it is selected from the group consisting of: alkyl, alkoxy, thioalkyl, aryl, CO-aryl, heteroaryl, amino and carboxyalkyl; Z is selected from the group consisting of: alkyl, alkoxy, thioalkyl, halogen, aryl, CO-aryl, CN, heteroaryl and carboxyalkyl; and its physiologically acceptable salts, hydrates and solvates. Claim 6: A medicament comprising a compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, hydrate or solvate thereof. Claim 7: A pharmaceutical composition comprising: A) a pharmacologically effective amount of a compound of the formula (1), according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as active ingredient; and B) optionally, at least one pharmaceutically acceptable carrier and / or at least one pharmaceutically acceptable auxiliary substance. Claim 10: A process for preparing a compound of the formula (1) according to any one of claims 1 to 5, characterized in that compounds of the formula (2) in which Hal means a halogen, selected from the group consisting of chlorine, and bromine , preferably chlorine, are reacted with an alcohol of the formula (3) to give compounds of the formula (1). Claim 13: The use of a compound according to any one of claims 1 to 5 or of its physiologically acceptable salts, hydrates and solvates, as a medicament for mammals, preferably humans.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07118932 | 2007-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070949A1 true AR070949A1 (en) | 2010-05-19 |
Family
ID=39495891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080104465A AR070949A1 (en) | 2007-10-19 | 2008-10-14 | COMPOUNDS DERIVED FROM SULFAMATE FOR MEDICAL USE, MEDICINES AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, PROCEDURES TO PREPARE THESE COMPOUNDS AND THEIR USE |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2207766A1 (en) |
JP (1) | JP2011500641A (en) |
CN (1) | CN101801921A (en) |
AR (1) | AR070949A1 (en) |
AU (1) | AU2008313663A1 (en) |
CA (1) | CA2700568A1 (en) |
MX (1) | MX2010002869A (en) |
RU (1) | RU2010119646A (en) |
TW (1) | TW200927090A (en) |
WO (1) | WO2009050252A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120263714A1 (en) * | 2009-10-21 | 2012-10-18 | Bayer Intellectual Property Gmbh | Substituted halophenoxybenzamide derivatives |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
HUE033583T2 (en) * | 2012-06-21 | 2017-12-28 | Eisai R&D Man Co Ltd | Novel indanesulfamide derivative |
CN111801096B (en) | 2018-03-20 | 2024-03-05 | 卫材R&D管理有限公司 | Therapeutic agent for epilepsy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
-
2008
- 2008-10-14 AR ARP080104465A patent/AR070949A1/en unknown
- 2008-10-15 TW TW097139465A patent/TW200927090A/en unknown
- 2008-10-17 WO PCT/EP2008/064007 patent/WO2009050252A1/en active Application Filing
- 2008-10-17 MX MX2010002869A patent/MX2010002869A/en not_active Application Discontinuation
- 2008-10-17 CN CN200880107423A patent/CN101801921A/en active Pending
- 2008-10-17 CA CA2700568A patent/CA2700568A1/en not_active Abandoned
- 2008-10-17 JP JP2010529391A patent/JP2011500641A/en active Pending
- 2008-10-17 AU AU2008313663A patent/AU2008313663A1/en not_active Abandoned
- 2008-10-17 EP EP08838679A patent/EP2207766A1/en not_active Withdrawn
- 2008-10-17 RU RU2010119646/04A patent/RU2010119646A/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2010119646A (en) | 2011-11-27 |
AU2008313663A1 (en) | 2009-04-23 |
MX2010002869A (en) | 2010-03-31 |
JP2011500641A (en) | 2011-01-06 |
TW200927090A (en) | 2009-07-01 |
CN101801921A (en) | 2010-08-11 |
EP2207766A1 (en) | 2010-07-21 |
CA2700568A1 (en) | 2009-04-23 |
WO2009050252A1 (en) | 2009-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059957A1 (en) | DERIVATIVES OF SPIROINDOLINONE, METHODS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CANCER. | |
AR083849A1 (en) | ESPIRO-OXINDOL MDM2 ANTAGONISTS | |
CO6470846A2 (en) | AMINOBUTICAL DERIVATIVES REPLACED AS NEPRILISINE INHIBITORS | |
UY27336A1 (en) | 4-PIPERACINYLINDOL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | |
UY29562A1 (en) | AMINO BENZOIL HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS | |
UY29087A1 (en) | ADAMANTILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USE | |
AR063602A1 (en) | DERIVATIVES OF SPIROINDOLINONE, PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM AND THEIR USE IN THE OBTAINING OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ONCOLOGICAL DISORDERS. | |
UY32462A (en) | NEW BIFENYLL DERIVATIVES FOR HEPATITIS C 644 VIRUS INFECTION TREATMENT | |
UY28578A1 (en) | AMIDA DERIVATIVES | |
AR047531A1 (en) | DERIVATIVES 1H-TIENO (2,3-C) PIRAZOL USEFUL AS QUINASE INHIBITORS | |
UY30316A1 (en) | SUBSTITUTED DERIVATIVES OF BENZAMIDS, NICOTINAMIDS, PROPANAMIDS, ACETAMIDS AND CARBOXAMIDS N- (2- (PIPERIDIN-1-ILMETIL) CICLOHEXIL) REPLACED, PREPARATION PROCESSES, COMPOSITIONS CONTAINING AND APPLICATIONS | |
PE20091349A1 (en) | COMPOUNDS DERIVED FROM SPIRO 1,3,4-TIADIAZOL AS INHIBITORS OF KSP KINESINE ACTIVITY | |
AR066063A1 (en) | TRIAZOL DERIVATIVES THAT ARE SMO ANTAGONISTS | |
AR048501A1 (en) | COMPOSITE BENZOAZABICICLOHEPTANO DIMERICO, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE IT | |
AR045155A1 (en) | DERIVATIVES OF 6-INDOLILSULFONAMIDS, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS | |
AR054508A1 (en) | BENCILPIPERAZINE COMPOSITE, ITS USE TO PREPARE A MEDICINAL PRODUCT, PROCEDURES FOR THE PREPARATION OF SUCH COMPOUND AND INTERMEDIATE COMPOUNDS, SUCH INTERMEDIARY COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE TO PREPARE IT | |
AR062737A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND DERIVED FROM ARIL-AZABICICLO, CORRESPONDING COMPOUND AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
DOP2019000076A (en) | DERIVATIVES OF CHROMANO, ISOCROMANO AND DIHYDROISOBENZOFURANOS AS NEGATIVE ALOSTERIC MODULATORS OF mGluR2, COMPOSITIONS AND ITS USE | |
CO6460737A2 (en) | N - ((1R, 2S, 5R) -5- (TERT -BUTILAMINO) -2 - ((S) -3- (7-TERT-BUTILPIRAZOLO [1.5-A] [1.3.5] TRAIZIN -4-ILAMINO) -2-OXOPIRROLIDIN-1-IL) CICLOHEXIL) ACETAMIDE, A DUAL MODULATOR OF THE ACTIVITY OF THE RECEIVER OF CHEMIOKINS, CRYSTAL FORMS AND PROCESSES | |
UY28356A1 (en) | DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, PREPARATIONS OF THE SAME AND ITS USES | |
AR045156A1 (en) | DERIVATIVES OF 5-INDOLILSULFONAMIDS, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS | |
AR061185A1 (en) | HETEROCICLICAL COMPOUNDS AS INHIBITORS OF HSP90. PHARMACEUTICAL COMPOSITIONS. | |
AR065348A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A NON-PEPTIDIC AGONIST OF THE TPO RECEIVER, PHARMACEUTICAL COMBINATION WITH AN ANTI-NEOPLASIC AGENT AND ITS USES TO PREPARE A CANCER TREATMENT MEDICINAL PRODUCT | |
CL2019001023A1 (en) | Naphthyridinone derivatives and their use in the treatment of arrhythmia. | |
UY29739A1 (en) | DERIVATIVES OF AMIDAS OR PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, PROCESSES OF PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND APPLICATIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |